Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4Lymphoid 4Dermatologic 3Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 631Radiotherapy 339pembrolizumab 329Cetuximab 284Docetaxel 226Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 77toripalimab 75Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 50Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 44130-nm albumin-bound paclitaxel 44tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
urelumab × Head & Neck × Clear all
NCT02110082 2017-04-19

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Bristol-Myers Squibb

Phase 1 Completed
66 enrolled
GastrointestinalHead & Neck

Head and Neck Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡